Joel Lewis, Director at GALECTIN THERAPEUTICS INC (GALT), bought 1,000 shares at $4.81 ($5K) on 2019-01-29, disclosed to the SEC on 2019-01-30.
Open-market purchase of $5k GALT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| GALT | SELL | 2025-11-19 | $231K | — | Filing → |
| GALT | SELL | 2025-11-12 | $11K | — | Filing → |
| GALT | SELL | 2025-11-07 | $1K | — | Filing → |